ResVita Bio
ResVita Bio
  • Home
  • Careers
  • More
    • Home
    • Careers
  • Home
  • Careers

About Us

At ResVita Bio, we are dedicated to restoring and maintaining the vitality of your skin. Using cutting-edge technologies in synthetic biology and metabolic engineering, we are pioneering the development of a safe and versatile skin microbial platform. Our innovative approach involves applying engineered cells topically in a moisturizer to continuously deliver targeted therapies that address the underlying causes of chronic skin diseases.

Technology

Our technology at ResVita Bio revolutionizes skin health by targeting the underlying protein imbalances that contribute to aging and disease. Traditionally, small molecules have been used to mimic missing proteins in treating skin conditions, but they often lack precision and can have toxic effects due to their long half-lives and systemic absorption. Gene therapy holds great promise in delivering the necessary proteins, but viral vectors used in traditional gene therapy approaches can pose serious toxicity concerns and lack adjustability. 


ResVita Bio takes a different approach by utilizing our proprietary cells, which are applied topically in a moisturizer. These cells have been extensively dermatologically tested and proven to be non-irritating and non-allergenic. Importantly, our cells can be easily washed off at any point, ensuring safety and flexibility. By applying our cells topically, they continuously produce the missing proteins directly in the skin, restoring the delicate protein balances essential for skin health. This precise and adjustable delivery system offers a transformative solution for various skin diseases and conditions. 

Leadership

Dr. Amin Zargar

Dr. Jay Keasling

Dr. Jay Keasling

Chief Executive Officer  

Dr. Jay Keasling

Dr. Jay Keasling

Dr. Jay Keasling

Co-Founder & Board Member

Designations & Awards

News

The story of Resvita Bio: How a bakar fellows passion for cell therapies became a reality
ResVita Bio receives Rare Pediatric Disease Designation for RVB-001 as a Treatment for Netherton Syndrome
National Institute of Health (NIH) awards ResVita Bio an SBIR grant to develop RVB-001 as a treatment for Netherton Syndrome
National Institute of Health (NIH) awards ResVita Bio an SBIR grant to develop RVB-101 as a treatment for Severe Atopic Dermatitis

ResVita Bio

2625 Durant Avenue, Berkeley, CA, 94720

Copyright © 2023 ResVita Bio - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept